Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

Overview of attention for article published in American Journal of Gastroenterology, August 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 3 news outlets
policy: 4 policy sources
twitter: 24 X users

patent: 7 patents
wikipedia: 1 Wikipedia page
guideline: 20 clinical guideline sources

Readers on

mendeley: 924 Mendeley

So far, Altmetric has seen 8 policy documents that reference this research output.

Avaluació de la seguretat, l'eficàcia, l'efectivitat clínica, l'eficiència i els aspectes organitzatius de la implementació dels sistemes de dosificació basada en models per al tractament de la malaltia inflamatòria intestinal

Cited by Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) on 06 Oct 2026

AQUAS's mission is to provide knowledge, directly applicable, to support decision-making based on the best evidence in the Catalan health system

risankizumab - Patient and Clinician Group input

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 14 Feb 2025

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Provider Specialization in Inflammatory Bowel Diseases: Quality of Care and Outcomes

Cited by Centers for Disease Control and Prevention (CDC) on 26 Nov 2024

CDC is America’s leading public health agency, dedicated to saving and protecting the health of Americans. CDC monitors health, informs decisionmakers, and provides people with information so they can take responsibility for their own health.

risankizumab - Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 12 May 2023

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity, including 4 additional policy documents.